logo

For the Inventor, By the Inventor

Bjärred, Sweden

Peter Edman

This inventor holds 6 USPTO granted patents. Top assignee: Astrazeneca Ab. Active years: 2001-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter Edman. Retrieved from https://idiyas.com/inventor/peter-edman-6z7ibh95

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 4.1

ph-index = 5

Forward Citations = 172(Granted Patents)


Location History:

  • Kullavik, SE (2002)
  • Bjärred, SE (2001 - 2005)

Company Filing History:

goldMedal6 out of 1,534 
 
Astrazeneca Ab
 patents

Years Active: 2001-2005

Loading Chart...
6 patents (USPTO):Explore Patents
1. 6846801 - Systemic administration of a therapeutic preparation (2005-01-25),
2. 6794357 - Compositions for inhalation (2004-09-21),
3. 6632456 - Compositions for inhalation (2003-10-14),
4. 6610653 - Therapeutic preparation for inhalation (2003-08-26),
5. 6436902 - Therapeutic preparations for inhalation (2002-08-20),
6. 6306440 - Therapeutic preparation for inhalation (2001-10-23),

Title: Innovations by Peter Edman

Introduction

Peter Edman is a notable inventor based in Bjärred, Sweden. He has made significant contributions to the field of therapeutic preparations, particularly in the administration of insulin. With a total of 6 patents to his name, Edman continues to push the boundaries of medical innovation.

Latest Patents

Among his latest patents is a groundbreaking method for systemic administration of a therapeutic preparation. This method involves treating patients in need of insulin by introducing an effective amount of a dry powder containing insulin and an enhancer compound into the lower respiratory tract. This innovative approach aims to enhance the absorption of insulin in the lungs, providing a new avenue for treatment. Another notable patent involves dry powder compositions suitable for inhalation from a dry powder inhaler device. These compositions comprise a pharmacologically active polypeptide and a surfactant, with at least 50% of the total mass consisting of primary particles having a diameter of less than 10 microns.

Career Highlights

Peter Edman is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on developing advanced therapeutic solutions that can significantly improve patient outcomes.

Collaborations

Edman has collaborated with several esteemed colleagues, including Ann Charlotte Birgit Johansson and Carl Magnus Olof Dahlbäck. These collaborations have fostered a productive environment for innovation and research.

Conclusion

Peter Edman's contributions to the field of therapeutic preparations, particularly in insulin administration, highlight his role as a key innovator in the medical industry. His patents reflect a commitment to improving patient care through advanced technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…